243990827	243990827	CD	B-NP	O
|	|	NN	I-NP	O
IH	IH	NN	I-NP	O
|	|	NN	I-NP	O
91535275	91535275	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
9804210	9804210	CD	B-NP	O
|	|	CC	I-NP	O
8/3/2005	8/3/2005	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
VENTRICULAR	VENTRICULAR	NNP	I-NP	I-protein
TACHYCARDIA	TACHYCARDIA	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Unsigned	Unsigned	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
6/12/2005	6/12/2005	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Unsigned	Unsigned	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
4/4/2005	4/4/2005	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
BOGGIANO	BOGGIANO	NN	B-NP	O
,	,	,	O	O
COLUMBUS	COLUMBUS	NNP	B-NP	O
WILTON	WILTON	NNP	I-NP	O
MD	MD	NNP	I-NP	O
PRINCIPAL	PRINCIPAL	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
:	:	:	O	O
Ventricular	Ventricular	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
Mr.	Mr.	NNP	B-NP	O
Forbess	Forbess	NNP	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
75-year-old	75-year-old	JJ	I-NP	O
man	man	NN	I-NP	O
with	with	IN	B-PP	O
ischemic	ischemic	JJ	B-NP	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
EF	EF	NN	I-NP	O
of	of	IN	B-PP	O
15	15	CD	B-NP	O
%	%	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
ICD	ICD	NN	I-NP	O
and	and	CC	O	O
biventricular	biventricular	JJ	B-NP	O
pacer	pacer	NN	I-NP	O
,	,	,	O	O
moderate	moderate	JJ	B-NP	O
aortic	aortic	JJ	I-NP	O
stenosis	stenosis	NN	I-NP	O
who	who	WP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
on	on	IN	B-PP	O
July	July	NNP	B-NP	O
,	,	,	O	O
2005	2005	CD	B-NP	O
after	after	IN	B-SBAR	O
his	his	PRP$	B-NP	O
ICD	ICD	NN	I-NP	B-protein
fired	fire	VBN	B-VP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
for	for	IN	B-PP	O
ventricular	ventricular	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
notes	note	VBZ	B-VP	O
a	a	DT	B-NP	O
productive	productive	JJ	I-NP	O
cough	cough	NN	I-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
subjective	subjective	JJ	I-NP	O
fever	fever	NN	I-NP	O
and	and	CC	I-NP	O
nausea	nausea	NN	I-NP	O
and	and	CC	I-NP	O
vomiting	vomiting	NN	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
seen	see	VBN	I-VP	O
in	in	IN	B-PP	O
Electrophysiology	Electrophysiology	NNP	B-NP	O
Clinic	Clinic	NNP	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
low	low	JJ	I-NP	O
grade	grade	NN	I-NP	O
fever	fever	NN	I-NP	O
of	of	IN	B-PP	O
100.0	100.0	CD	B-NP	O
at	at	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
electively	electively	RB	I-VP	O
admitted	admit	VBN	I-VP	O
but	but	CC	O	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
way	way	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
floor	floor	NN	I-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
ICD	ICD	NN	I-NP	B-protein
fired	fire	VBD	B-VP	O
again	again	RB	B-ADVP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
lidocaine	lidocaine	NN	B-NP	O
and	and	CC	B-PP	O
after	after	IN	B-PP	O
a	a	DT	B-NP	O
third	third	JJ	I-NP	O
firing	firing	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
ICD	ICD	NN	I-NP	B-protein
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
begun	begin	VBN	I-VP	O
on	on	IN	B-PP	O
amiodarone	amiodarone	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
then	then	RB	B-ADVP	O
became	become	VBD	B-VP	O
short	short	RB	B-ADVP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
pulmonary	pulmonary	JJ	B-NP	O
edema	edema	NN	I-NP	O
,	,	,	O	O
requiring	require	VBG	B-VP	O
intubation	intubation	NN	B-NP	O
.	.	.	O	O

Chest	Ch	JJS	B-NP	O
x-ray	x-ray	NN	I-NP	B-DNA
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
upper	upper	JJ	I-NP	O
lobe	lobe	NN	I-NP	O
white	white	JJ	B-VP	O
out	out	RP	B-PRT	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
taken	take	VBN	I-VP	O
to	to	TO	B-PP	O
Cath	Cath	NNP	B-NP	O
for	for	IN	B-PP	O
possible	possible	JJ	B-NP	O
ischemia	ischemia	NN	I-NP	O
contributing	contribute	VBG	B-VP	O
to	to	TO	B-PP	O
his	his	PRP$	B-NP	O
ventricular	ventricular	JJ	I-NP	O
fibrillation	fibrillation	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
proximal	proximal	JJ	I-NP	O
80	80	CD	I-NP	O
%	%	NN	I-NP	O
LAD	LAD	NN	I-NP	O
lesion	lesion	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
mid	mid	JJ	I-NP	O
70	70	CD	I-NP	O
%	%	NN	I-NP	O
LAD	LAD	NN	I-NP	O
lesion	lesion	NN	I-NP	O
which	which	WDT	B-NP	O
were	be	VBD	B-VP	O
both	both	DT	O	O
stented	stente	VBD	B-VP	O
with	with	IN	B-PP	O
Seifer	Seifer	NN	B-NP	O
stents	stent	NNS	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
also	also	RB	B-ADVP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
60	60	CD	I-NP	O
%	%	NN	I-NP	O
D1	D1	NN	I-NP	O
lesion	lesion	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
angioplastied	angioplastie	VBN	I-VP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
residual	residual	JJ	I-NP	O
40	40	CD	I-NP	O
%	%	NN	I-NP	O
lesion	lesion	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
also	also	RB	B-ADVP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
70	70	CD	I-NP	O
%	%	NN	I-NP	O
left	leave	VBD	B-VP	O
circumflex	circumflex	NN	B-NP	O
lesion	lesion	NN	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
catheterization	catheterization	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Cardiac	Cardiac	NNP	I-NP	O
Intensive	Intensive	NNP	I-NP	O
Care	Care	NNP	I-NP	O
Unit	Unit	NNP	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
his	his	PRP$	B-NP	O
amiodarone	amiodarone	NN	I-NP	O
load	load	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
further	further	JJ	I-NP	O
arrhythmias	arrhythmia	NNS	I-NP	O
during	during	IN	B-PP	O
his	his	PRP$	B-NP	O
ICU	ICU	NN	I-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
extubated	extubate	VBN	I-VP	O
the	the	DT	B-NP	O
following	follow	VBG	I-NP	O
day	day	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
diuresed	diurese	VBN	I-VP	O
for	for	IN	B-PP	O
congestive	congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
also	also	RB	B-ADVP	O
began	begin	VBD	B-VP	O
treatment	treatment	NN	B-NP	O
for	for	IN	B-PP	O
both	both	DT	B-NP	O
community	community	NN	I-NP	O
acquired	acquire	VBD	B-VP	O
pneumonia	pneumonia	NN	B-NP	O
and	and	CC	I-NP	O
aspiration	aspiration	NN	I-NP	O
pneumonia	pneumonia	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
transferred	transfer	VBN	I-VP	O
out	out	IN	B-PP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
Intensive	Intensive	JJ	I-NP	O
Care	Care	NNP	I-NP	O
Unit	Unit	NNP	I-NP	O
on	on	IN	B-PP	O
May	May	NNP	B-NP	O
,	,	,	O	O
2005	2005	CD	B-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
Coronary	Coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
EF	EF	NN	B-NP	B-protein
of	of	IN	B-PP	O
15	15	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
ICD	ICD	NN	I-NP	O
and	and	CC	O	O
biventricular	biventricular	JJ	B-NP	O
pacer	pacer	NN	I-NP	O
,	,	,	O	O
moderate	moderate	JJ	B-NP	O
aortic	aortic	JJ	I-NP	O
stenosis	stenosis	NN	I-NP	O
,	,	,	O	O
paroxysmal	paroxysmal	JJ	B-NP	O
atrial	atrial	JJ	I-NP	O
fibrillation	fibrillation	NN	I-NP	O
,	,	,	O	O
diabetes	diabetes	NN	B-NP	O
,	,	,	O	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
baseline	baseline	NN	I-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
1.5	1.5	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
hypothyroidism	hypothyroidism	NN	B-NP	O
.	.	.	O	O

HOME	HOME	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Synthroid	Synthroid	JJ	B-ADJP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Lasix	Lasix	NN	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Coumadin	Coumadin	NN	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Lopressor	Lopressor	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Lorazepam	Lorazepam	NN	B-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Colace	Colace	NNP	B-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Prilosec	Prilosec	NNP	B-NP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
No	No	DT	B-NP	O
known	know	VBN	I-NP	O
drug	drug	NN	I-NP	O
allergies	allergy	NNS	I-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	JJ	B-NP	O
EXAMINATION	EXAMINATION	NN	I-NP	O
:	:	:	O	O
Upon	Upon	IN	B-PP	O
transfer	transfer	NN	B-NP	O
out	out	IN	B-PP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
Intensive	Intensive	JJ	I-NP	B-DNA
Care	Care	NNP	I-NP	I-DNA
Unit	Unit	NNP	I-NP	I-DNA
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
pulse	pulse	NN	I-NP	O
of	of	IN	B-PP	O
81	81	CD	B-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
108/74	108/74	CD	I-NP	O
,	,	,	O	O
oxygen	oxygen	NN	B-NP	O
saturation	saturation	NN	I-NP	O
of	of	IN	B-PP	O
84	84	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
97	97	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
four	four	CD	B-NP	O
liters	liter	NNS	I-NP	O
.	.	.	O	O

JVP	JVP	NN	B-NP	B-protein
of	of	IN	B-PP	O
14	14	CD	B-NP	O
cm	cm	NN	I-NP	O
.	.	.	O	O

Lungs	Lung	NNS	B-NP	O
with	with	IN	B-PP	O
bibasilar	bibasilar	JJ	B-NP	O
rales	rale	NNS	I-NP	O
.	.	.	O	O

Cardiac	Cardiac	JJ	B-NP	O
exam	exam	NN	I-NP	O
revealed	reveal	VBD	B-VP	O
a	a	DT	B-NP	O
regular	regular	JJ	I-NP	O
rate	rate	NN	I-NP	O
and	and	CC	I-NP	O
rhythm	rhythm	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
abdomen	abdoman	NNS	I-NP	O
was	be	VBD	B-VP	O
soft	soft	JJ	B-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
pulsatile	pulsatile	JJ	I-NP	O
liver	liver	NN	I-NP	O
and	and	CC	O	O
mild	mild	JJ	B-NP	O
right	right	RB	I-NP	O
lower	low	JJR	I-NP	O
quadrant	quadrant	JJ	I-NP	O
tenderness	tenderness	NN	I-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
rebound	rebound	NN	I-NP	O
or	or	CC	I-NP	O
guarding	guarding	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
extremities	extremity	NNS	I-NP	O
had	have	VBD	B-VP	O
trace	trace	NN	B-NP	O
pitting	pitting	NN	I-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

Examination	Examination	NN	B-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
skin	skin	NN	I-NP	O
revealed	reveal	VBD	B-VP	O
vesicles	vesicle	NNS	B-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
sternum	sternum	NN	I-NP	O
above	above	IN	B-PP	O
the	the	DT	B-NP	O
nipple	nipple	NN	I-NP	O
line	line	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
papular	papular	JJ	I-NP	O
rash	rash	NN	I-NP	O
extending	extend	VBG	B-VP	O
in	in	IN	B-PP	O
a	a	DT	B-NP	O
dermatomal	dermatomal	JJ	I-NP	O
pattern	pattern	NN	I-NP	O
around	around	IN	B-PP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
side	side	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
back	back	RB	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
midline	midline	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
extension	extension	NN	B-NP	O
down	down	IN	B-PP	O
the	the	DT	B-NP	O
inner	inner	JJ	I-NP	O
portion	portion	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
upper	upper	JJ	I-NP	O
arm	arm	NN	I-NP	O
.	.	.	O	O

LABS	LABS	NN	B-NP	B-protein
:	:	:	O	O
Labs	Lab	NNS	B-NP	B-protein
were	be	VBD	B-VP	O
significant	significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
2.1	2.1	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
a	a	DT	B-NP	O
negative	negative	JJ	I-NP	O
troponin	troponin	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

IMPRESSION	IMPRESSION	NN	B-NP	O
:	:	:	O	O
75-year-old	75-year-old	JJ	B-NP	O
man	man	NN	I-NP	O
with	with	IN	B-PP	O
ischemic	ischemic	JJ	B-NP	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O
admitted	admit	VBN	B-VP	O
with	with	IN	B-PP	O
ventricular	ventricular	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
of	of	IN	B-PP	O
unclear	unclear	JJ	B-NP	O
etiology	etiology	NN	I-NP	O
,	,	,	O	O
though	though	IN	B-SBAR	O
possibilities	possibility	NNS	B-NP	O
include	include	VBP	B-VP	O
underlying	underlie	VBG	I-VP	O
infection	infection	NN	B-NP	O
or	or	CC	O	O
cardiac	cardiac	JJ	B-NP	O
ischemia	ischemia	NN	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	NNP	B-NP	O
COURSE	COURSE	NNP	I-NP	O
BY	BY	NNP	I-NP	O
SYSTEM	SYSTEM	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
taken	take	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Cath	Cath	NNP	I-NP	O
Lab	Lab	NNP	I-NP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
stents	stent	NNS	B-NP	O
placed	place	VBN	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
LAD	LAD	NN	I-NP	B-protein
with	with	IN	B-PP	O
other	other	JJ	B-NP	O
residual	residual	JJ	I-NP	O
disease	disease	NN	I-NP	O
remaining	remain	VBG	B-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
regimen	regimen	NN	I-NP	O
of	of	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
,	,	,	O	O
Plavix	Plavix	NN	B-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
statin	statin	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
often	often	RB	B-ADVP	O
refused	refuse	VBD	B-VP	O
to	to	TO	I-VP	O
take	take	VB	I-VP	O
the	the	DT	B-NP	O
statin	statin	NN	I-NP	O
,	,	,	O	O
though	though	IN	B-SBAR	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
recommended	recommend	VBN	I-VP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
low	low	JJ	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
ace	ace	NN	B-NP	O
inhibitor	inhibitor	NN	I-NP	O
which	which	WDT	B-NP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
frequently	frequently	RB	B-ADVP	O
refused	refuse	VBD	B-VP	O
as	as	RB	B-ADVP	O
well	well	RB	I-ADVP	O
.	.	.	O	O

We	We	PRP	B-NP	O
would	would	MD	B-VP	O
recommend	recommend	VB	I-VP	O
starting	start	VBG	I-VP	O
a	a	DT	B-NP	O
beta-blocker	beta-blocker	NN	I-NP	O
when	when	WRB	B-ADVP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
more	more	RBR	B-ADJP	O
stable	stable	JJ	I-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
diuresed	diurese	VBN	I-VP	O
with	with	IN	B-PP	O
Lasix	Lasix	NN	B-NP	O
until	until	IN	B-SBAR	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
uvolemic	uvolemic	JJ	B-ADJP	O
and	and	CC	O	O
then	then	RB	B-VP	O
resumed	resume	VBD	I-VP	O
his	his	PRP$	B-NP	O
home	home	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
Lasix	Lasix	NNP	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

An	An	DT	B-NP	O
echo	echo	NN	I-NP	O
during	during	IN	B-PP	O
admission	admission	NN	B-NP	O
showed	show	VBD	B-VP	O
an	an	DT	B-NP	O
EF	EF	NN	I-NP	B-protein
of	of	IN	B-PP	O
15	15	CD	B-NP	O
%	%	NN	I-NP	O
with	with	IN	B-PP	O
moderate	moderate	JJ	B-NP	O
aortic	aortic	JJ	I-NP	O
stenosis	stenosis	NN	I-NP	O
.	.	.	O	O

For	For	IN	B-PP	O
his	his	PRP$	B-NP	O
episodes	episode	NNS	I-NP	O
of	of	IN	B-PP	O
ventricular	ventricular	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
begun	begin	VBN	I-VP	O
on	on	IN	B-PP	O
an	an	DT	B-NP	O
amiodarone	amiodarone	NN	I-NP	O
load	load	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
goal	goal	NN	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
total	total	NN	I-NP	O
of	of	IN	B-PP	O
10	10	CD	B-NP	O
grams	gram	NNS	I-NP	O
at	at	IN	B-PP	O
which	which	WDT	B-NP	O
point	point	NN	I-NP	O
he	he	PRP	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
tapered	taper	VBN	I-VP	O
to	to	TO	B-PP	O
40	40	CD	B-NP	O
mg	mg	NN	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
one	one	CD	B-NP	O
day	day	NN	I-NP	O
remaining	remain	VBG	B-VP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
amiodarone	amiodarone	NN	I-NP	O
load	load	NN	I-NP	O
and	and	CC	O	O
should	should	MD	B-VP	O
begin	begin	VB	I-VP	O
the	the	DT	B-NP	O
400	400	CD	I-NP	O
mg	mg	NN	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
dose	dose	NN	I-NP	O
on	on	IN	B-PP	O
September	September	NNP	B-NP	O
,	,	,	O	O
2005	2005	CD	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
monitored	monitor	VBN	I-VP	O
on	on	IN	B-PP	O
telemetry	telemetry	NN	B-NP	O
without	without	IN	B-PP	O
significant	significant	JJ	B-NP	O
event	event	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Kolopajlo	Kolopajlo	NNP	I-NP	O
in	in	IN	B-PP	O
Electrophysiology	Electrophysiology	NNP	B-NP	O
Clinic	Clinic	NNP	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
Disease	Disease	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
for	for	IN	B-PP	O
both	both	DT	B-NP	O
community	community	NN	I-NP	O
acquired	acquire	VBD	B-VP	O
pneumonia	pneumonia	NN	B-NP	O
and	and	CC	I-NP	O
aspiration	aspiration	NN	I-NP	O
pneumonia	pneumonia	NN	I-NP	O
with	with	IN	B-PP	O
cefotaxime	cefotaxime	NN	B-NP	O
,	,	,	I-NP	O
azithromycin	azithromycin	NN	I-NP	O
and	and	CC	I-NP	O
Flagyl	Flagyl	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
completed	complete	VBD	B-VP	O
a	a	DT	B-NP	O
5-day	5-day	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
azithromycin	azithromycin	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
is	be	VBZ	B-VP	O
still	still	RB	B-ADVP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
process	process	NN	I-NP	O
of	of	IN	B-PP	O
completing	complete	VBG	B-VP	O
a	a	DT	B-NP	O
total	total	JJ	I-NP	O
10	10	CD	I-NP	O
day	day	NN	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
cephalosporin	cephalosporin	NN	B-NP	O
and	and	CC	I-NP	O
Flagyl	Flagyl	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
one	one	CD	B-NP	O
more	more	JJR	I-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
therapy	therapy	NN	B-NP	O
remaining	remain	VBG	B-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
shingles	shingle	NNS	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
reports	report	NNS	I-NP	O
experiencing	experience	VBG	B-VP	O
pain	pain	NN	B-NP	O
that	that	WDT	B-NP	O
started	start	VBD	B-VP	O
on	on	IN	B-PP	O
his	his	PRP$	B-NP	O
back	back	NN	I-NP	O
before	before	IN	B-PP	O
the	the	DT	B-NP	O
rash	rash	NN	I-NP	O
appeared	appear	VBD	B-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
rash	rash	NN	I-NP	O
was	be	VBD	B-VP	O
present	present	JJ	B-ADJP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
acyclovir	acyclovir	NN	B-NP	O
on	on	IN	B-PP	O
May	May	NNP	B-NP	O
,	,	,	O	O
2005	2005	CD	B-NP	O
and	and	CC	O	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
stopped	stop	VBN	I-VP	O
on	on	IN	B-PP	O
November	November	NNP	B-NP	O
,	,	,	O	O
2005	2005	CD	B-NP	O
given	give	VBN	B-PP	O
that	that	IN	B-SBAR	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
likely	likely	RB	B-NP	O
little	little	JJ	I-NP	O
utility	utility	NN	I-NP	O
of	of	IN	B-PP	O
treatment	treatment	NN	B-NP	O
begun	begin	VBN	B-VP	O
greater	great	JJR	B-NP	O
than	than	IN	I-NP	O
48	48	CD	I-NP	O
hours	hour	NNS	I-NP	O
into	into	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
and	and	CC	O	O
because	because	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
preferred	prefer	VBD	B-VP	O
not	not	RB	O	O
to	to	TO	B-VP	O
take	take	VB	I-VP	O
the	the	DT	B-NP	O
medication	medication	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Renal	Renal	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
baseline	baseline	NN	I-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
1.5	1.5	CD	B-NP	O
.	.	.	O	O

Creatinine	Creatinine	NN	B-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
elevated	elevate	VBN	I-VP	O
to	to	TO	B-PP	O
2.1	2.1	CD	B-NP	O
,	,	,	O	O
but	but	CC	O	O
improved	improve	VBD	B-VP	O
back	back	RB	B-ADVP	O
to	to	TO	B-PP	O
baseline	baseline	NN	B-NP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-VP	O
discharge	discharge	VB	I-VP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Endocrine	Endocrine	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
diabetes	diabetes	NN	B-NP	O
,	,	,	O	O
but	but	CC	O	O
was	be	VBD	B-VP	O
on	on	IN	B-PP	O
no	no	DT	B-NP	O
medications	medication	NNS	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
received	receive	VBD	B-VP	O
a	a	DT	B-NP	O
diabetic	diabetic	JJ	I-NP	O
diet	diet	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
regular	regular	JJ	I-NP	O
insulin	insulin	NN	I-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
during	during	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

Hemoglobin	Hemoglobin	NN	B-NP	B-protein
A1c	A1c	NN	I-NP	O
was	be	VBD	B-VP	O
6.6	6.6	CD	B-NP	O
,	,	,	O	O
indicating	indicate	VBG	B-VP	O
poor	poor	JJ	B-NP	O
glycemic	glycemic	JJ	I-NP	O
control	control	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
low	low	JJ	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
glipizide	glipizide	NN	B-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
regular	regular	JJ	I-NP	O
insulin	insulin	NN	I-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
was	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
also	also	RB	B-ADVP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
hypothyroidism	hypothyroidism	NN	B-NP	O
.	.	.	O	O

TSH	TSH	NN	B-NP	O
was	be	VBD	B-VP	O
checked	check	VBN	I-VP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
1.6	1.6	CD	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
within	within	IN	B-PP	O
normal	normal	JJ	B-NP	O
limits	limit	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
low	low	JJ	I-NP	O
calcium	calcium	NN	I-NP	O
level	level	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
vitamin	vitamin	NN	B-NP	O
D	D	NN	I-NP	O
deficient	deficient	JJ	B-ADJP	O
.	.	.	O	O

We	We	PRP	B-NP	O
have	have	VBP	B-VP	O
started	start	VBN	I-VP	O
supplementation	supplementation	NN	B-NP	O
of	of	IN	B-PP	O
vitamin	vitamin	NN	B-NP	B-protein
D.	D.	NNP	B-NP	I-protein
5	5	CD	I-NP	I-protein
.	.	.	O	O

Heme	Heme	NN	B-NP	B-protein
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
anticoagulated	anticoagulate	VBN	I-VP	O
for	for	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
and	and	CC	O	O
low	low	JJ	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
held	hold	VBN	I-VP	O
but	but	CC	O	O
then	then	RB	B-VP	O
restarted	restart	VBD	I-VP	O
on	on	IN	B-PP	O
October	October	NNP	B-NP	O
,	,	,	O	O
2005	2005	CD	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
is	be	VBZ	B-VP	O
now	now	RB	B-ADVP	O
therapeutic	therapeutic	JJ	B-ADJP	O
.	.	.	O	O

Goal	Goal	NNP	B-NP	O
INR	INR	NNP	I-NP	O
is	be	VBZ	B-VP	O
2-3	2-3	CD	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
monitored	monitor	VBN	I-VP	O
and	and	CC	O	O
Coumadin	Coumadin	NN	B-NP	O
adjusted	adjust	VBN	B-VP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
also	also	RB	B-ADVP	O
has	have	VBZ	B-VP	O
iron	iron	NN	B-NP	O
deficiency	deficiency	NN	I-NP	O
anemia	anemia	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
GI	GI	NN	B-NP	O
evaluation	evaluation	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
future	future	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
begun	begin	VBN	I-VP	O
on	on	IN	B-PP	O
iron	iron	NN	B-NP	O
supplementation	supplementation	NN	I-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
frequently	frequently	RB	B-ADVP	O
refuses	refuse	VBZ	B-VP	O
to	to	TO	I-VP	O
take	take	VB	I-VP	O
this	this	DT	B-NP	O
medication	medication	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Prophylaxis	Prophylaxis	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
therapeutic	therapeutic	JJ	B-ADJP	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Code	Code	NN	B-NP	O
status	status	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
full	full	JJ	B-NP	O
code	code	NN	I-NP	O
.	.	.	O	O

FOLLOW	FOLLOW	RB	B-ADVP	O
UP	UP	NN	B-NP	O
INSTRUCTIONS	INSTRUCTIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Blood	Blood	NN	B-NP	O
draw	draw	NN	I-NP	O
in	in	IN	B-PP	O
2-3	2-3	CD	B-NP	O
days	day	NNS	I-NP	O
to	to	TO	B-VP	O
monitor	monitor	VB	I-VP	O
INR	INR	NN	B-NP	B-protein
and	and	CC	I-NP	O
creatinine	creatinine	NN	I-NP	O
.	.	.	O	O

Please	Please	VB	B-VP	O
adjust	adjust	JJ	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
dose	dose	NN	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
goal	goal	NN	I-NP	O
INR	INR	NN	I-NP	O
of	of	IN	B-PP	O
2-3	2-3	NN	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Taper	Taper	NN	B-NP	O
amiodarone	amiodarone	NN	I-NP	O
to	to	TO	B-PP	O
40	40	CD	B-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
on	on	IN	B-PP	O
September	September	NNP	B-NP	O
,	,	,	O	O
2005	2005	CD	B-NP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
loading	loading	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
400	400	CD	B-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
3	3	CD	I-NP	O
.	.	.	O	O

Please	Please	VB	B-VP	O
encourage	encourage	VB	I-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
to	to	TO	B-VP	O
take	take	VB	I-VP	O
simvastatin	simvastatin	NN	B-NP	O
,	,	,	I-NP	O
captopril	captopril	NN	I-NP	O
and	and	CC	I-NP	O
iron	iron	NN	I-NP	O
supplements	supplement	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
frequently	frequently	RB	B-ADVP	O
refuses	refuse	VBZ	B-VP	O
to	to	TO	I-VP	O
take	take	VB	I-VP	O
these	these	DT	B-NP	O
recommended	recommended	JJ	I-NP	O
medications	medication	NNS	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Last	Last	JJ	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
antibiotics	antibiotic	NNS	B-NP	O
is	be	VBZ	B-VP	O
March	March	NNP	B-NP	O
,	,	,	O	O
2005	2005	CD	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
GI	GI	NN	B-NP	O
evaluation	evaluation	NN	I-NP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
iron	iron	NN	I-NP	O
deficiency	deficiency	NN	I-NP	O
anemia	anemia	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Tylenol	Tylenol	NN	B-NP	O
650	650	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
q.	q.	NN	I-NP	O
6	6	CD	B-NP	O
hours	hour	NNS	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
headache	headache	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Amiodarone	Amiodarone	NN	B-NP	O
400	400	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
x4	x4	CD	B-NP	O
doses	dose	NNS	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Aspirin	Aspirin	NN	B-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Dulcolax	Dulcolax	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
constipation	constipation	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Vitamin	Vitamin	NN	B-NP	O
D	D	NN	I-NP	O
or	or	CC	O	O
calcitriol	calcitriol	NN	B-NP	O
0.25	0.25	CD	I-NP	O
mcg	mcg	NN	I-NP	O
PO	PO	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Captopril	Captopril	NNP	B-NP	O
3	3	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
7	7	CD	I-NP	O
.	.	.	O	O

Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
8	8	CD	I-NP	O
.	.	.	O	O

Iron	Iron	NN	B-NP	B-protein
325	325	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
daily	daily	RB	B-ADVP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Lasix	Lasix	NN	B-NP	B-protein
80	80	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
daily	daily	RB	B-ADVP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Glipizide	Glipizide	NN	B-NP	B-protein
2.5	2.5	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
daily	daily	RB	B-ADVP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Atrovent	Atrovent	NNP	B-NP	O
inhaler	inhaler	IN	B-PP	O
2	2	CD	B-NP	O
puffs	puff	NNS	I-NP	O
inhaler	inhal	JJR	B-NP	O
q.i.d.	q.i.d.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
wheezing	wheezing	NN	I-NP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Synthroid	Synthroid	JJ	B-NP	O
175	175	CD	I-NP	O
mcg	mcg	NN	I-NP	O
PO	PO	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

13	13	CD	B-NP	O
.	.	.	O	O

Ativan	Ativan	IN	B-PP	O
0.5	0.5	CD	B-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
nausea	nausea	NN	I-NP	O
or	or	CC	I-NP	O
anxiety	anxiety	NN	I-NP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Flagyl	Flagyl	NN	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
x4	x4	CD	B-NP	O
doses	dose	NNS	I-NP	O
.	.	.	O	O

15	15	CD	B-NP	O
.	.	.	O	O

Senna	Senna	NNP	B-NP	O
tablets	tablet	VBZ	B-VP	O
2	2	CD	B-NP	O
tablets	tablet	NNS	I-NP	O
PO	PO	NN	I-NP	O
b.i.d.	b.i.d.	JJ	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
constipation	constipation	NN	I-NP	O
.	.	.	O	O

16	16	CD	B-NP	O
.	.	.	O	O

Trazodone	Trazodone	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
insomnia	insomnia	NN	I-NP	O
.	.	.	O	O

17	17	CD	B-NP	O
.	.	.	O	O

Coumadin	Coumadin	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
18	18	CD	I-NP	O
.	.	.	O	O

MSIR	MSIR	NN	B-NP	B-protein
7.5	7.5	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
q.	q.	NN	I-NP	I-protein
6	6	CD	B-NP	I-protein
hours	hour	NNS	I-NP	I-protein
p.r.n.	p.r.n.	JJ	B-NP	I-protein
pain	pain	NN	I-NP	I-protein
.	.	.	O	O

19	19	CD	B-NP	O
.	.	.	O	O

Simvastatin	Simvastatin	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
20	20	CD	I-NP	O
.	.	.	O	O

Ambien	Ambien	IN	B-PP	O
10	10	CD	B-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
insomnia	insomnia	NN	I-NP	O
.	.	.	O	O

21	21	CD	B-NP	O
.	.	.	O	O

Plavix	Plavix	NN	B-NP	B-protein
75	75	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
daily	daily	RB	B-ADVP	O
.	.	.	O	O

22	22	CD	B-NP	O
.	.	.	O	O

Nexium	Nexium	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

23	23	CD	B-NP	O
.	.	.	O	O

Amiodarone	Amiodarone	NN	B-NP	B-protein
400	400	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
daily	daily	RB	B-ADVP	O
,	,	,	O	O
starting	start	VBG	B-VP	O
on	on	IN	B-PP	O
September	September	NNP	B-NP	O
,	,	,	O	O
2005	2005	CD	B-NP	O
.	.	.	O	O

24	24	CD	B-NP	O
.	.	.	O	O

Cefpodoxime	Cefpodoxime	NN	B-NP	O
200	200	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
x2	x2	NN	I-NP	O
doses	dose	NNS	I-NP	O
.	.	.	O	O

25	25	CD	B-NP	O
.	.	.	O	O

Reglan	Reglan	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
q.i.d.	q.i.d.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
nausea	nausea	NN	I-NP	O
.	.	.	O	O

FOLLOW	FOLLOW	RB	B-ADVP	O
UP	UP	NN	B-NP	O
APPOINTMENTS	APPOINTMENTS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Dr.	Dr.	NNP	B-NP	O
Provencal	Provencal	NNP	I-NP	O
in	in	IN	B-PP	O
Cardiology	Cardiology	NNP	B-NP	O
at	at	IN	B-PP	O
La	La	NNP	B-NP	O
Hospital	Hospital	NNP	I-NP	O
,	,	,	O	O
phone	phone	NN	B-NP	O
number	number	NN	I-NP	O
776-170-8696	776-170-8696	CD	I-NP	O
.	.	.	O	O

Please	Please	NN	B-NP	O
schedule	schedule	NN	I-NP	O
next	next	JJ	B-NP	O
available	available	JJ	I-NP	O
appointment	appointment	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Dr.	Dr.	NNP	B-NP	O
Opie	Opie	NNP	I-NP	O
,	,	,	O	O
primary	primary	JJ	B-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
at	at	IN	B-PP	O
LHO	LHO	NN	B-NP	B-protein
.	.	.	O	O

Please	Please	NN	B-NP	O
schedule	schedule	NN	I-NP	O
next	next	JJ	B-NP	O
available	available	JJ	I-NP	O
appointment	appointment	NN	I-NP	O
.	.	.	O	O

DIET	DIET	NN	B-NP	O
:	:	:	O	O
House	House	NNP	B-NP	O
diet	diet	NN	I-NP	O
,	,	,	O	O
low	low	JJ	B-NP	O
cholesterol	cholesterol	NN	I-NP	O
,	,	,	O	O
low	low	JJ	B-NP	O
saturated	saturate	VBN	I-NP	O
fat	fat	NN	I-NP	O
.	.	.	O	O

Diabetic	Diabetic	JJ	B-NP	O
2100	2100	CD	I-NP	O
calories	calorie	NNS	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
,	,	,	O	O
2	2	CD	B-NP	O
grams	gram	NNS	I-NP	O
sodium	sodium	NN	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
3-1657523	3-1657523	CD	B-NP	O
MCS	MCS	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
MCKEVITT	MCKEVITT	NNP	B-NP	O
,	,	,	O	O
CLAUDIO	CLAUDIO	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
DUMENY	DUMENY	NNP	B-NP	O
,	,	,	O	O
ISIAH	ISIAH	NNP	B-NP	O
GRANT	GRANT	NNP	I-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
7204481	7204481	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
9/13/05	9/13/05	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
9/13/05	9/13/05	CD	B-NP	O

